Loading organizations...
§ Private Profile · Cambridge, MA, USA
A biopharmaceutical company discovering and developing novel treatments for rare neurodegenerative and metabolic disorders.
Amylyx Pharmaceuticals is a Cambridge, Massachusetts-based biopharmaceutical company that develops novel therapies for severe neurodegenerative and metabolic diseases, including Wolfram syndrome and Progressive Supranuclear Palsy. The publicly traded biopharmaceutical firm generated approximately $381 million in net product revenue in 2023 through its primary ALS drug, Relyvrio, before voluntarily withdrawing the treatment from North American markets in April 2024 following a failed Phase 3 clinical trial. Following this market withdrawal, the enterprise implemented a 71 percent workforce reduction from its previous headcount of nearly 400 employees to conserve capital. Backed by institutional investors including Bain Capital Life Sciences and Morningside Venture, the company recently acquired the Phase 3-ready drug candidate avexitide from Eiger BioPharmaceuticals for $35.1 million to expand its clinical pipeline. Amylyx Pharmaceuticals was founded in 2013 by Joshua Cohen and Justin Klee.
Amylyx Pharmaceuticals has raised $171.9M across 4 funding rounds.
Amylyx Pharmaceuticals has raised $171.9M in total across 4 funding rounds.
Amylyx Pharmaceuticals has raised $171.9M in total across 4 funding rounds.
Amylyx Pharmaceuticals's investors include Viking Global Investors, Belinda Termeer, 683 Capital Management, Bain Capital Life Sciences, Falcon Edge Capital, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management.
Amylyx Pharmaceuticals has raised $171.9M across 4 funding rounds. Most recently, it raised $135.0M Series C in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 20, 2021 | $135M Series C | Viking Global Investors | Belinda Termeer, 683 Capital Management, Bain Capital Life Sciences, Falcon Edge Capital, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Woodline Partners | Announced |
| Jul 1, 2020 | $30M Series B | Isaac Cheng | — | Announced |
| Aug 22, 2016 | $5M Series A | Isaac Cheng | Henri Termeer, Felix Coerper | Announced |
| Nov 17, 2015 | $1.9M Venture Round | Merit Cudkowicz, Cure Alzheimer | — | Announced |